Digestive Diseases and Sciences

, Volume 44, Issue 1, pp 186–189 | Cite as

Case Report: Myasthenia Gravis Another Autoimmune Disease Associated with Hepatitis C Virus Infection

  • Setijoso Eddy
  • Robberecht Wim
  • Van Eycken Peter
  • Roskams Tanja
  • Tack Jan Van Steenbergen Werner
Article
MYASTHENIA GRAVIS HEPATITIS C ACETYLCHOLINE RECEPTOR AUTOIMMUNE DISEASES MOLECULAR MIMICRY 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Phillips LH: The epidemiology of myasthenia gravis. Neurol Clin North Am 12:263–271, 1994Google Scholar
  2. 2.
    Drachman DB: Myasthenia gravis. N Engl J Med 330:1797–1810, 1994Google Scholar
  3. 3.
    Hopkins LC: Clinical features of myasthenia gravis. Neurol Clin North Am 12:243–261, 1994Google Scholar
  4. 4.
    Richman DP, Agius MA: Acquired myasthenia gravis. Neurol Clin North Am 12:273–284, 1994Google Scholar
  5. 5.
    Berrih-Aknin S: Myasthenia gravis, a mode l of organ–specific autoimmune disease. J Autoimmun 8:139–143, 1995Google Scholar
  6. 6.
    Vincent A: Aetiological factors in development of myasthenia gravis. Adv Neuroimmunol 4:355–371, 1994Google Scholar
  7. 7.
    Stefansson K, Dieperink ME, Richman DP, Gomez CM, Marton LS: Sharing of antigenic determinants between the nicotinic acetylcholine receptor and proteins in, and Klebsiella pneum oniae. N Engl J Med 312:221–225, 1985Google Scholar
  8. 8.
    Schwimmbeck PL, Dyrberg T, Drachman DB, Oldstone MBA: Molecular mimicry and myasthenia gravis. An autoantigenic site of the ace tylcholine receptor alfa–subunit that has biologic activity and reacts immunochemically with herpes simplex virus. J Clin Invest 84:1174–1180, 1989Google Scholar
  9. 9.
    Verma A, Berger JR: Myasthe nia gravis associated with dual infection of HIV and HTLV–I. Muscle Nerve 18:1355–1356, 1995Google Scholar
  10. 10.
    Authier F-J, De Grissac N, Degos J-D, Ghe rardi RK: Transient myasthenia gravis during HIV infection. Muscle Nerve 18:914–916, 1995Google Scholar
  11. 11.
    Strassburg CP, Obermayer-Straub P, Manns MP: Autoimmunity in hepatitis C and D virus infection. J Viral Hepatitis 3:49–59, 1996Google Scholar
  12. 12.
    Pawlotsky J-M, Ben Yahia M, Andre C, e t al: Immunological disorders in C virus chronic active hepatitis: A prospective case–control study. Hepatology 19:841–848, 1994Google Scholar
  13. 13.
    Picollo G, Franciotta D, Ve rsino M, Alfonsi E, Lombardi M, Poma G: Myasthenia gravis in a patient with chronic active hepatitis C during interferon–alfa treatment. J Neurol Neurosurg Psych 60:348, 1996Google Scholar
  14. 14.
    Mase G, Zorzon M, Biasutti E, Vitrani B, Cazzato G, Urban F, Frezza M: Development of myasthenia gravis during interferon–alfa treatme nt for anti–HCV positive chronic hepatitis. J Neurol Neurosurg Psychiatry 60:348–349, 1996Google Scholar
  15. 15.
    Quilichini R, Mazzerbo F, Baume D, Amiel O, Lafeuillade A, Pellegrino P: Myasthénie au cours d'un traitement par l'interfé ron alpha. Presse Med 24:1178, 1995Google Scholar
  16. 16.
    Vincent A: Acetylcholine receptor autoantibodies. In Autoantibodies. JB Peter, Y Shoenfield (eds). Amsterdam, Elsevier Science BV, 1996, pp 1–9Google Scholar
  17. 17.
    Reyes H: Striational autoantibodies. In Autoantibodies. JB Peter, Y Shoenfield (eds). Amsterdam, Elsevier Science BV, 1996, pp 805–809Google Scholar
  18. 18.
    Yap SH, Willems M, Van den Oord J, Habets W, Middeldorp JM, Hellings JA, Nevens F, Moshage H, Desmet V, Fevery J: Detection of hepatitis C virus antigen by immunohistochemical staining: A histological marker of hepatitis C virus infection. J Hepatol 20:275–281, 1994Google Scholar
  19. 19.
    Booth JCL, Thomas HC: Pathogenesis of chronic hepatitis C and associated clinical manifestations. Bailliere's Clin Gastroenterol 10:257–274, 1996Google Scholar
  20. 20.
    Colombo M: The natural history of hepatitis C. Bailliere's Clin Gastroenterol 10:275–288, 1996Google Scholar
  21. 21.
    Obermayer-Strauss P, Manns MP: Cytochrome s P–450 and UDP–glucuronosyltransferases as hepatocellular autoantigens. Bailliere's Clin Gastroenterol 10:501–532, 1996Google Scholar
  22. 22.
    Michel G, Ritter A, Gerken G, Meyer Zum Büschenfelde KH, Decher G, Manns M: Anti–GOR and hepatitis C virus in autoimmune liver diseases. Lancet 339:267–269, 1992Google Scholar
  23. 23.
    Yamamoto AM, Cresteil D, Homberg JC, Alvarez F: Characterization of anti-liver-kidney microsome antibody (anti–LKM1) from hepatitis C virus-positive and-negative sera. Gastroenterology 104:1762–1767, 1993Google Scholar
  24. 24.
    Lunel F, Abuaf N, Frangeul L, Grippon P, Perrin M, Le Coz Y, Valla D, Borotto E, Yamamoto AM, Huraux JM, Opolon P, Homberg JC: Liver:kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology 16:630–636, 1992Google Scholar
  25. 25.
    Garcia-Buey L, Garcia-Monzon C, Rodriguez S, Borque MJ, Garcia–Sanchez A, Iglesias R, De castro M, Mateos FG, Vicario JL, Balas A, Moreno-Otero R: Latent autoimmune hepatitis triggered during Interferon therapy in patients with chronic hepatitis C. Gastroenterology 108:1770–1777, 1995Google Scholar
  26. 26.
    Shindo M, Di Bisceglie AM, Hoofnagle JH: Acute exace rbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 102:1406–1408, 1992Google Scholar
  27. 27.
    Ruiz-Moreno M, Rua MJ, Carreno V, Quiroga JA, Manns M, Meyer zum Büschenfelde KH: Autoimmune chronic hepatitis C type 2 manifested during interferon therapy in children. J Hepatol 12:265–266, 1991Google Scholar
  28. 28.
    Renault PF, Hoofnagle JH: Side effects of alpha interferon. Semin Liver Dis 9:273–277, 1989Google Scholar
  29. 29.
    Marcellin P, Pouteau M, Renard P, Grynblat JM, Colas Linhart N, Bardet P, Bok B, Benhamou JP: Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C. Gut 33:855–856, 1992Google Scholar
  30. 30.
    Marcellin P, Pouteau M, Messian O, Bok B, Erlinger S, Benhamou JP: Virus de l'hé patite C, interfé ron alpha et dysthyro ïdie. Gastroenterol Clin Biol 17:887–891, 1993Google Scholar
  31. 31.
    Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, Garcia-Monzon C, Arranz A, Borque MJ, Moreno–Otero R: Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interfe ron-alpha therapy. Clin Endocrinol 44:635–642, 1996Google Scholar
  32. 32.
    Peters M: Mechanisms of action of Interferons. Semin Liver Dis 9:235–239, 1989Google Scholar
  33. 33.
    Tilg H: New insights into the me chanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 112:1017–1021, 1997Google Scholar

Copyright information

© Plenum Publishing Corporation 1999

Authors and Affiliations

  • Setijoso Eddy
  • Robberecht Wim
  • Van Eycken Peter
  • Roskams Tanja
  • Tack Jan Van Steenbergen Werner

There are no affiliations available

Personalised recommendations